 Mirati Therapeutics Inc NASDAQ: MRTX announced results from the 600mg BID dose cohort of the Phase 12 KRYSTAL1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. 